FAST
57
-3
CINF
53
3
URI
60
-6
HSIC
45
5
KR
36
-6
CTAS
53
-3
NOC
41
9
ETR
65
2
PYPL
52
-2
AN
50
-5
SRE
63
2
FE
44
5
SO
57
6
PDCO
29
2
ALLE
37
-4
AIV
64
4
PGR
59
-3
GME
66
-5
NVDA
52
-5
CAH
48
-6
FAST
57
-3
CINF
53
3
URI
60
-6
HSIC
45
5
KR
36
-6
CTAS
53
-3
NOC
41
9
ETR
65
2
PYPL
52
-2
AN
50
-5
SRE
63
2
FE
44
5
SO
57
6
PDCO
29
2
ALLE
37
-4
AIV
64
4
PGR
59
-3
GME
66
-5
NVDA
52
-5
CAH
48
-6
Financhill
Back

Poseida Therapeutics 10K Form

Sell
45

PSTX
Poseida Therapeutics

Last Price:
2.75
Seasonality Move:
20.58%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PSTX News And Ratings

See the #1 stock for the next 7 days that we like better than PSTX

PSTX Financial Statistics

Sales & Book Value

Annual Sales: $64.7M
Cash Flow: $-10.24M
Price / Cash Flow: 0
Annual Sales: $0.90
Price / Book: 3.59

Profitability

EPS (TTM): -0.62000
Net Income (TTM): $-60.76M
Gross Margin: --
Return on Equity: -66.05%
Return on Assets: -21.23%

Poseida Therapeutics Earnings Forecast

Key Poseida Therapeutics Financial Ratios

  • The Research & Development expenses have been 242.29% of Revenue.
  • The Interest Expense is -7.03% of Operating Income.
  • The Net Earning history of PSTX is -190.76% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 2 years.

Poseida Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PSTX
CUSIP: 73730P
Website: poseida.com

Debt

Debt-to-Equity Ratio: 0.68
Current Ratio: 3.2
Quick Ratio: 3.14

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PSTX Technical Analysis vs Fundamental Analysis

Sell
45
Poseida Therapeutics (PSTX) is a Sell

Is Poseida Therapeutics a Buy or a Sell?